Recipharm AB publishes its interim report January-March 2020
January – March 2020 · Consort Medical Plc consolidated from February 2020 · Continued solid organic growth · Net sales amounted to SEK 2,593 million (1,812), an increase of 43% · EBITDA increased by 48% and amounted to SEK 431 million (291) corresponding to an EBITDA margin of 16.6% (16.1) · EBITA increased by 56% and amounted to SEK 267 million (171) corresponding to an EBITA margin of 10.3% (9.4) · Operating profit (EBIT) amounted to SEK -29 million (111), adjusted Operating profit amounted to SEK 164 (111). · Profit after tax amounted to SEK -230 million (79)